Show simple item record

dc.contributor.authorOlivier, Jonathan
dc.contributor.authorLi, Weiyu
dc.contributor.authorNieboer, Daan
dc.contributor.authorHelleman, Jozien
dc.contributor.authorRoobol, Monique
dc.contributor.authorGnanapragasam, Vincent
dc.contributor.authorFrydenberg, Mark
dc.contributor.authorSugimoto, Mikio
dc.contributor.authorCarroll, Peter
dc.contributor.authorMorgan, Todd M
dc.contributor.authorValdagni, Riccardo
dc.contributor.authorRubio-Briones, Jose
dc.contributor.authorRobert, Grégoire
dc.contributor.authorStricker, Phillip
dc.contributor.authorHayen, Andrew
dc.contributor.authorSchoots, Ivo
dc.contributor.authorHaider, Masoom
dc.contributor.authorMoore, Caroline M
dc.contributor.authorDenton, Brian
dc.contributor.authorVillers, Arnauld
dc.contributor.authorMovember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 Consortium
dc.date.accessioned2022-02-11T00:31:31Z
dc.date.available2022-02-11T00:31:31Z
dc.date.issued2022-01
dc.identifier.issn2666-1691
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/333883
dc.description.abstractBACKGROUND: The inclusion criterion for active surveillance (AS) is low- or intermediate-risk prostate cancer. The predictive value of the presence of a suspicious lesion at magnetic resonance imaging (MRI) at the time of inclusion is insufficiently known. OBJECTIVE: To evaluate the percentage of patients needing active treatment stratified by the presence or absence of a suspicious lesion at baseline MRI. DESIGN SETTING AND PARTICIPANTS: A retrospective analysis of the data from the multicentric AS GAP3 Consortium database was conducted. The inclusion criteria were men with grade group (GG) 1 or GG 2 prostate cancer combined with prostate-specific antigen <20 ng/ml. We selected a subgroup of patients who had MRI at baseline and for whom MRI results and targeted biopsies were used for AS eligibility. Suspicious MRI was defined as an MRI lesion with Prostate Imaging Reporting and Data System (PI-RADS)/Likert ≥3 and for which targeted biopsies did not exclude the patient for AS. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was treatment free survival (FS). The secondary outcomes were histological GG progression FS and continuation of AS (discontinuation FS). RESULTS AND LIMITATIONS: The study cohort included 2119 patients (1035 men with nonsuspicious MRI and 1084 with suspicious MRI) with a median follow-up of 23 (12-43) mo. For the whole cohort, 3-yr treatment FS was 71% (95% confidence interval [CI]: 69-74). For nonsuspicious MRI and suspicious MRI groups, 3-yr treatment FS rates were, respectively, 80% (95% CI: 77-83) and 63% (95% CI: 59-66). Active treatment (hazard ratio [HR] = 2.0, p < 0.001), grade progression (HR = 1.9, p < 0.001), and discontinuation of AS (HR = 1.7, p < 0.001) were significantly higher in the suspicious MRI group than in the nonsuspicious MRI group. CONCLUSIONS: The risks of switching to treatment, histological progression, and AS discontinuation are higher in cases of suspicious MRI at inclusion. PATIENT SUMMARY: Among men with low- or intermediate-risk prostate cancer who choose active surveillance, those with suspicious magnetic resonance imaging (MRI) at the time of inclusion in active surveillance are more likely to show switch to treatment than men with nonsuspicious MRI.
dc.format.mediumElectronic-eCollection
dc.publisherElsevier BV
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectActive surveillance
dc.subjectDiscontinuation
dc.subjectMagnetic resonance imaging
dc.subjectNomogram
dc.subjectProstate cancer
dc.subjectWorldwide
dc.titleProstate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium.
dc.typeArticle
dc.date.updated2022-02-10T11:15:42Z
prism.endingPage67
prism.publicationDate2022
prism.publicationNameEur Urol Open Sci
prism.startingPage59
prism.volume35
dc.identifier.doi10.17863/CAM.81299
dcterms.dateAccepted2021-11-18
rioxxterms.versionofrecord10.1016/j.euros.2021.11.006
rioxxterms.versionVoR
dc.identifier.eissn2666-1683
rioxxterms.typeJournal Article/Review
cam.issuedOnline2022-01-03
cam.depositDate2022-02-10
pubs.licence-identifierapollo-deposit-licence-2-1
pubs.licence-display-nameApollo Repository Deposit Licence Agreement


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial-NoDerivatives 4.0 International